The role of serum albumin in the metabolism of Boc5: Molecular identification, species differences and contribution to plasma metabolism

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 360-369

  Ge, Guang Bo ^a   Ai, Chun Zhi ^a   Hu, Wen Bing ^b   Hou, Jie ^c   Zhu, Liang Liang ^a   He, Gui Yuan ^a   Fang, Zhong Ze ^a   Liang, Si Cheng ^a   Wang, Fu Yi ^b   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b INSTITUTE OF CHEMISTRY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Albumin; Boc5; Pseudo esterase; Species differences; Transesterification

Indexed keywords

BOC 5; BOVINE SERUM ALBUMIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DEGRADATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL PIG; HUMAN; HUMAN TISSUE; HYDROLYSIS; MICHAELIS MENTEN KINETICS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BIOTRANSFORMATION; CYCLOBUTANES; ESTERASES; HALF-LIFE; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; INTESTINES; LIVER; MALE; MICROSOMES; MOLECULAR DOCKING SIMULATION; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SWINE;

EID: 84871413418     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.11.011     Document Type: Article

References (47)

1. Y. Ashani, J.O. Peggins 3rd, and B.P. Doctor Mechanism of inhibition of cholinesterases by huperzine A Biochem. Biophys. Res. Commun. 184 2 1992 719 726
2. M. Aviram, S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Arterioscler. Thromb. Vasc. Biol. 18 10 1998 1617 1624
3. A.A. Bhattacharya, S. Curry, and N.P. Franks Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures J. Biol. Chem. 275 49 2000 38731 38738
4. A.A. Bhattacharya, T. Grune, and S. Curry Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin J. Mol. Biol. 303 5 2000 721 732
5. D. Chen, J. Liao, N. Li, C. Zhou, Q. Liu, G. Wang, R. Zhang, S. Zhang, L. Lin, K. Chen, X. Xie, F. Nan, A.A. Young, and M.W. Wang A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice Proc. Natl. Acad. Sci. USA 104 3 2007 943 948
6. D.H. Cheng, H. Ren, and X.C. Tang Huperzine A, a novel promising acetylcholinesterase inhibitor Neuroreport 8 1 1996 97 101
7. L. Di, E.H. Kerns, Y. Hong, and H. Chen Development and application of high throughput plasma stability assay for drug discovery Int. J. Pharm. 297 1-2 2005 110 119
8. P.J. Eddershaw, A.P. Beresford, and M.K. Bayliss ADME/PK as part of a rational approach to drug discovery Drug Discov. Today 5 9 2000 409 414
9. G.R. Fulcher, M. Walker, C. Catalano, L. Agius, and K.G. Alberti Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects Diabetes 41 11 1992 1400 1408
10. J. Ghuman, P.A. Zunszain, I. Petitpas, A.A. Bhattacharya, M. Otagiri, and S. Curry Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 353 1 2005 38 52
11. E. Giacobini Cholinesterase inhibitors: new roles and therapeutic alternatives Pharmacol. Res. 50 4 2004 433 440
12. M.I. Grossman, H.C. Moeller, and L. Palm Effect of lipemia and heparin on free fatty acid concentration of serum in humans Proc. Soc. Exp. Biol. Med. 90 1 1955 106 109
13. Z. Grubic, D. Sket, and M. Brzin Iso-OMPA-induced potentiation of soman toxicity in rat correlates with the inhibition of plasma carboxylesterases Arch. Toxicol. 62 5 1988 398 399
14. N. Guan, W. Gao, M. He, M. Zheng, X. Xu, X. Wang, and M.W. Wang Dynamic monitoring of beta-cell injury with impedance and rescue by glucagon-like peptide-1 Anal. Biochem. 423 1 2012 61 69
15. M. He, N. Guan, W.W. Gao, Q. Liu, X.Y. Wu, D.W. Ma, D.F. Zhong, G.B. Ge, C. Li, X.Y. Chen, L. Yang, J.Y. Liao, and M.W. Wang A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities Acta Pharmacol. Sin. 33 2 2012 148 154
16. M. He, H. Su, W. Gao, S.M. Johansson, Q. Liu, X. Wu, J. Liao, A.A. Young, T. Bartfai, and M.W. Wang Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice PLoS One 5 12 2010 e14205
17. X.M. He, and D.C. Carter Atomic structure and chemistry of human serum albumin Nature 358 6383 1992 209 215
18. J.L. Iltz, D.E. Baker, S.M. Setter, and R. Keith Campbell Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus Clin. Ther. 28 5 2006 652 665
19. A.N. Jain Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities J. Comput. Aid. Mol. Des. 10 5 1996 427 440
20. R. Konsoula, and M. Jung In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors Int. J. Pharm. 361 1-2 2008 19 25
21. Y. Kurono, I. Kushida, H. Tanaka, and K. Ikeda Esterase-like activity of human serum albumin. VIII. Reaction with amino acid p-nitrophenyl esters Chem. Pharm. Bull. (Tokyo) 40 8 1992 2169 2172
22. Y. Kurono, H. Yamada, H. Hata, Y. Okada, T. Takeuchi, and K. Ikeda Esterase-like activity of human serum albumin. IV. Reactions with substituted aspirins and 5-nitrosalicyl esters Chem. Pharm. Bull. (Tokyo) 32 9 1984 3715 3719
23. Y. Kurono, H. Yamada, and K. Ikeda Effects of drug binding on the esterase-like activity of human serum albumin. V. Reactive site towards substituted aspirins Chem. Pharm. Bull. (Tokyo) 30 1 1982 296 301
24. B. Li, M. Sedlacek, I. Manoharan, R. Boopathy, E.G. Duysen, P. Masson, and O. Lockridge Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma Biochem. Pharmacol. 70 11 2005 1673 1684
25. F. Lallemand, P. Perottet, O. Felt-Baeyens, W. Kloeti, F. Philippoz, J. Marfurt, K. Besseghir, and R. Gurny A water-soluble prodrug of cyclosporine A for ocular application: a stability study Eur. J. Pharm. Sci. 26 1 2005 124 129
26. F. Lin, and R. Wang Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists J. Mol. Model 15 1 2009 53 65
27. M.S. Liyasova, L.M. Schopfer, and O. Lockridge Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545 Biochem. Pharmacol. 79 5 2010 784 791
28. O. Lockridge, W. Xue, A. Gaydess, H. Grigoryan, S.J. Ding, L.M. Schopfer, S.H. Hinrichs, and P. Masson Pseudo-esterase activity of human albumin: slow turnover on tyrosine 411 and stable acetylation of 82 residues including 59 lysines J. Biol. Chem. 283 33 2008 22582 22590
29. J.J. Meier, and M.A. Nauck The potential role of glucagon-like peptide 1 in diabetes Curr. Opin. Invest. Drugs 5 4 2004 402 410
30. H.S. Moon, M.K. Kim, and M.H. Son The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes Arch. Pharm. Res. 34 7 2011 1041 1043
31. I. Petitpas, T. Grune, A.A. Bhattacharya, and S. Curry Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids J. Mol. Biol. 314 5 2001 955 960
32. G.M. Reaven, C. Hollenbeck, C.Y. Jeng, M.S. Wu, and Y.D. Chen Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM Diabetes 37 8 1988 1020 1024
33. J. Ruppert, W. Welch, and A.N. Jain Automatic identification and representation of protein binding sites for molecular docking Protein Sci. 6 3 1997 524 533
34. A. Salvi, P.A. Carrupt, J.M. Mayer, and B. Testa Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid Drug Metab. Dispos. 25 4 1997 395 398
35. A.T. Santomauro, G. Boden, M.E. Silva, D.M. Rocha, R.F. Santos, M.J. Ursich, P.G. Strassmann, and B.L. Wajchenberg Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects Diabetes 48 9 1999 1836 1841
36. K.W. Sloop, F.S. Willard, M.B. Brenner, J. Ficorilli, K. Valasek, A.D. Showalter, T.B. Farb, J.X. Cao, A.L. Cox, M.D. Michael, S.M. Gutierrez Sanfeliciano, M.J. Tebbe, and M.J. Coghlan Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 59 12 2010 3099 3107
37. M.A. Sogorb, V. Carrera, and E. Vilanova Hydrolysis of carbaryl by human serum albumin Arch. Toxicol. 78 11 2004 629 634
38. M. Stumvoll, B.J. Goldstein, and T.W. van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 9467 2005 1333 1346
39. H. Su, M. He, H. Li, Q. Liu, J. Wang, Y. Wang, W. Gao, L. Zhou, J. Liao, A.A. Young, and M.W. Wang Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice PLoS One 3 8 2008 e2892
40. L.F. Van Gaal, S.W. Gutkin, and M.A. Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol. 158 6 2008 773 784
41. T. Vilsboll The effects of glucagon-like peptide-1 on the beta cell Diabetes Obes. Metab. 11 Suppl 3 2009 11 18
42. M.W. Wang, Q. Liu, and C.H. Zhou Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery Acta Pharmacol. Sin. 31 9 2010 1026 1030
43. H. Watanabe, S. Tanase, K. Nakajou, T. Maruyama, U. Kragh-Hansen, and M. Otagiri Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity Biochem. J. 349 Pt 3 2000 813 819
44. K.N. White, J. Eggermont, and D.B. Hope Effect of the carboxylesterase inhibitor bis-(4-nitrophenyl)phosphate in vivo on aspirin hydrolase and carboxylesterase activities at first-pass sites of metabolism in the guinea pig Biochem. Pharmacol. 36 16 1987 2687 2688
45. D.M. Wilson, and L.I. Binder Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease Am. J. Pathol. 150 6 1997 2181 2195
46. F. Yang, C. Bian, L. Zhu, G. Zhao, Z. Huang, and M. Huang Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin J. Struct. Biol. 157 2 2007 348 355
47. H. Yki-Jarvinen, I. Puhakainen, and V.A. Koivisto Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation J. Clin. Endocrinol. Metab. 72 6 1991 1268 1277